CY2020014I1 - Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p - Google Patents

Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p

Info

Publication number
CY2020014I1
CY2020014I1 CY2020014C CY2020014C CY2020014I1 CY 2020014 I1 CY2020014 I1 CY 2020014I1 CY 2020014 C CY2020014 C CY 2020014C CY 2020014 C CY2020014 C CY 2020014C CY 2020014 I1 CY2020014 I1 CY 2020014I1
Authority
CY
Cyprus
Prior art keywords
dosage schedule
receptor agent
receptor
agent
schedule
Prior art date
Application number
CY2020014C
Other languages
English (en)
Other versions
CY2020014I2 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2020014(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2020014I2 publication Critical patent/CY2020014I2/el
Publication of CY2020014I1 publication Critical patent/CY2020014I1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CY2020014C 2008-12-22 2020-06-19 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p CY2020014I1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967308P 2008-12-22 2008-12-22
EP09167209 2009-08-04
EP09793546.4A EP2379069B1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist
PCT/EP2009/067618 WO2010072703A1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist

Publications (2)

Publication Number Publication Date
CY2020014I2 CY2020014I2 (el) 2020-11-25
CY2020014I1 true CY2020014I1 (el) 2020-11-25

Family

ID=41435196

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100469T CY1116321T1 (el) 2008-12-22 2015-05-27 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
CY2020014C CY2020014I1 (el) 2008-12-22 2020-06-19 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100469T CY1116321T1 (el) 2008-12-22 2015-05-27 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p

Country Status (35)

Country Link
US (2) US8492441B2 (el)
EP (1) EP2379069B1 (el)
JP (2) JP5657565B2 (el)
KR (1) KR101660555B1 (el)
CN (2) CN105213372A (el)
AR (1) AR074825A1 (el)
AU (1) AU2009331582B2 (el)
BR (1) BRPI0923213A2 (el)
CA (3) CA3105857C (el)
CY (2) CY1116321T1 (el)
DK (1) DK2379069T3 (el)
ES (1) ES2538413T3 (el)
FR (1) FR20C1022I2 (el)
HK (1) HK1159524A1 (el)
HR (1) HRP20150567T1 (el)
HU (2) HUE026400T2 (el)
IL (2) IL294658A (el)
JO (1) JO3044B1 (el)
LT (1) LTC2379069I2 (el)
LU (1) LUC00160I2 (el)
MA (1) MA32907B1 (el)
MX (2) MX2011006625A (el)
NL (1) NL301046I2 (el)
NO (1) NO2020017I1 (el)
NZ (1) NZ593427A (el)
PL (1) PL2379069T3 (el)
PT (1) PT2379069E (el)
RU (1) RU2561681C2 (el)
SG (1) SG171888A1 (el)
SI (1) SI2379069T1 (el)
TN (1) TN2011000281A1 (el)
TW (1) TWI472327B (el)
UY (1) UY32350A (el)
WO (1) WO2010072703A1 (el)
ZA (1) ZA201104102B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617628T5 (es) 2008-03-17 2020-06-01 Actelion Pharmaceuticals Ltd Régimen de dosificación para un agonista selectivo del receptor de S1P1
KR101624098B1 (ko) * 2008-07-23 2016-05-24 노파르티스 아게 스핑고신 1 포스페이트 수용체 조절제 및 근육 염증을 치료하기 위한 그의 용도
DK2379067T3 (en) 2008-12-22 2015-12-07 Novartis Ag Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN106309416A (zh) * 2010-05-06 2017-01-11 诺华股份有限公司 二芳基硫醚衍生物的给药方案
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
MX371290B (es) 2011-01-07 2020-01-24 Novartis Ag Formulaciones inmunosupresoras.
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
AU2012324867B2 (en) * 2011-10-21 2015-09-10 Novartis Ag Dosage regimen for an S1P receptor modulator or agonist
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
EP3199947A3 (en) * 2013-04-04 2017-09-13 Novartis AG Identifying patient response to s1p receptor modulator administration
AU2015246038C1 (en) * 2014-04-10 2018-05-31 Novartis Ag Immunosuppressant formulation
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
MY188764A (en) 2014-12-11 2021-12-30 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
EP4445956A2 (en) * 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
US20180042895A1 (en) * 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company OXIME ETHER COMPOUNDS
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
CA3073910A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
MX2020007326A (es) * 2017-09-29 2020-09-07 Novartis Ag Regimen de dosificacion de siponimod.
CN114599363A (zh) 2019-10-31 2022-06-07 爱杜西亚药品有限公司 Cxcr7拮抗剂与s1p1受体调节剂的组合
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
MX2023009249A (es) 2021-02-08 2023-10-23 Bausch Health Ireland Ltd Método para prevenir, tratar o mejorar la colitis ulcerosa.
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176819A (zh) * 1997-09-03 1998-03-25 王树生 一种解酒饮料及其制备方法
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US20050095292A1 (en) * 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
CN1913892A (zh) 2003-12-17 2007-02-14 大日本住友制药株式会社 药物组合物及联合药物
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 S1p 수용체 효능제의 투여 용법
CA2616204C (en) * 2005-09-09 2015-12-01 Labopharm Inc. Sustained drug release composition
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
SG187458A1 (en) * 2007-10-12 2013-02-28 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

Also Published As

Publication number Publication date
JP2015038097A (ja) 2015-02-26
CN105213372A (zh) 2016-01-06
BRPI0923213A2 (pt) 2016-01-26
JO3044B1 (ar) 2016-09-05
LUC00160I2 (el) 2021-07-06
IL213347A0 (en) 2011-07-31
CA3105857A1 (en) 2010-07-01
NL301046I1 (nl) 2020-06-17
PL2379069T3 (pl) 2015-08-31
CA2747992C (en) 2017-11-07
CY1116321T1 (el) 2017-02-08
IL213347B (en) 2019-11-28
MA32907B1 (fr) 2011-12-01
NZ593427A (en) 2013-11-29
JP2012513378A (ja) 2012-06-14
ES2538413T3 (es) 2015-06-19
CA2747992A1 (en) 2010-07-01
FR20C1022I2 (fr) 2021-06-11
JP5657565B2 (ja) 2015-01-21
PT2379069E (pt) 2015-07-03
IL294658A (en) 2022-09-01
LTPA2020513I1 (lt) 2020-07-27
CN102264363A (zh) 2011-11-30
DK2379069T3 (en) 2015-06-08
HRP20150567T1 (hr) 2015-08-14
AU2009331582B2 (en) 2014-03-13
US20110039818A1 (en) 2011-02-17
RU2561681C2 (ru) 2015-08-27
SG171888A1 (en) 2011-07-28
US8492441B2 (en) 2013-07-23
CY2020014I2 (el) 2020-11-25
NO2020017I1 (no) 2020-06-17
CA2981830A1 (en) 2010-07-01
TW201028147A (en) 2010-08-01
LTC2379069I2 (lt) 2022-05-25
HUE026400T2 (en) 2016-06-28
SI2379069T1 (sl) 2015-07-31
TWI472327B (zh) 2015-02-11
CA3105857C (en) 2023-08-01
NL301046I2 (nl) 2020-07-29
EP2379069B1 (en) 2015-03-04
US20130281712A1 (en) 2013-10-24
HK1159524A1 (en) 2012-08-03
HUS2000017I1 (hu) 2020-07-28
KR20110106399A (ko) 2011-09-28
AR074825A1 (es) 2011-02-16
TN2011000281A1 (en) 2012-12-17
EP2379069A1 (en) 2011-10-26
FR20C1022I1 (el) 2020-07-31
KR101660555B1 (ko) 2016-09-27
LUC00160I1 (el) 2020-06-19
WO2010072703A1 (en) 2010-07-01
MX2011006625A (es) 2011-09-28
ZA201104102B (en) 2012-02-29
UY32350A (es) 2010-04-30
JP5941110B2 (ja) 2016-06-29
MX367667B (es) 2019-08-30
AU2009331582A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CY2020014I2 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
CY2019031I1 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
LTPA2020529I1 (lt) Sfingozino fosfato receptorių nauji moduliatoriai
SMT201600222B (it) Formulazione di anticorpi
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
ES1070518Y (es) Dispositivo nivelador para la colocacion de piezas de recubrimiento
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI0916931A2 (pt) agentes terapêuticos
BR112012006957A2 (pt) regime de dosagem de um modulador de receptor de s1p
DK2367542T3 (da) Orale doseringsformer af bendamustin
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0906879A2 (pt) Compostos terapêuticos
TH116164B (th) การรวมกันของสารประกอบออกฤทธิ์
TH120083B (th) การรวมกันของสารประกอบออกฤทธิ์
ES1065747Y (es) Pieza de union central para mosquiteras
UA17730S (uk) Набір пристроїв для з`єднання щитів опалубки
DK2257548T3 (da) Terapeutiske forbindelser
TH115366B (th) รูปแบบขนาดยาของแข็ง